While methicillin-resistant Staphylococcus aureus (MRSA)
bacteremia has poor outcomes, we describe our experience with
Ceftobiprole mainly as a combination
therapy for the treatment of MRSA
bacteremia. All the cases of MRSA
bacteremia in our center at the King Abdulaziz Medical City (KAMC), Riyadh, that had undergone
Ceftobiprole treatment were included. We had six cases of MRSA
bacteremia between 2018 and 2019, secondary to different infectious syndromes including
endocarditis. There was a severe
infection that required intensive care unit (ICU) admission in four cases.
Ceftobiprole is used in combination with
vancomycin in four cases. On day 14, all cases had a favorable outcome with microbiological and clinical improvement. However, three patients died after months of suffering from
bacteremia from unrelated causes for the
infection. The clinical outcome in our series of treatment of MRSA
bacteremia using
Ceftobiprole was favorable. Further studies for the evaluation of the use of
Ceftobiprole in MRSA
bacteremia should be encouraged.